We demonstrated that olaparib improved TNBS-induced colitis in mice, reduced histological damage of the colon, diminished the number and length of the ulcers, inhibited proinflammatory cytokine production (IL-1β, IL-6), but it enhanced the level of anti-inflammatory cytokine IL-10. This evidence concerns the gene IL6 and colitis.